Download Free Sample Report

Circulating Tumor DNA Diagnostics Market, Global Outlook and Forecast 2023-2030

Circulating Tumor DNA Diagnostics Market, Global Outlook and Forecast 2023-2030

  • Published on : 09 March 2023
  • Pages :67
  • Report Code:SMR-7595940

Download Report PDF Instantly

Leave This Empty:

Secure

Report overview

This report aims to provide a comprehensive presentation of the global market for Circulating Tumor DNA Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor DNA Diagnostics. This report contains market size and forecasts of Circulating Tumor DNA Diagnostics in global, including the following market information:
Global Circulating Tumor DNA Diagnostics Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Circulating Tumor DNA Diagnostics market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Test Kits Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Circulating Tumor DNA Diagnostics include Grail, Inc., Guardant Health, Inc., Biodesix, Inc., Exosome Diagnostics, Freenome Inc., LungLife AI, Inc., Inivata Ltd., Personal Genome Diagnostics, Inc. and CellMax Life, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Circulating Tumor DNA Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Circulating Tumor DNA Diagnostics Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Circulating Tumor DNA Diagnostics Market Segment Percentages, by Type, 2022 (%)
Test Kits
Reagents
Global Circulating Tumor DNA Diagnostics Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Circulating Tumor DNA Diagnostics Market Segment Percentages, by Application, 2022 (%)
Hospitals
Diagnostics Laboratories
Research Laboratories
Academic Research Institutes
Global Circulating Tumor DNA Diagnostics Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Circulating Tumor DNA Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Circulating Tumor DNA Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Circulating Tumor DNA Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Grail, Inc.
Guardant Health, Inc.
Biodesix, Inc.
Exosome Diagnostics
Freenome Inc.
LungLife AI, Inc.
Inivata Ltd.
Personal Genome Diagnostics, Inc.
CellMax Life
Outline of Major Chapters:
Chapter 1: Introduces the definition of Circulating Tumor DNA Diagnostics, market overview.
Chapter 2: Global Circulating Tumor DNA Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Circulating Tumor DNA Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Circulating Tumor DNA Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.